Introduction {#section5-2042018819875406}
============

Sepsis is a leading cause of mortality in critical care worldwide.^[@bibr1-2042018819875406][@bibr2-2042018819875406]--[@bibr3-2042018819875406]^ In addition to mortality, sepsis may also cause long-term postsepsis cardiovascular disease.^[@bibr4-2042018819875406]^ The reported incidence of sepsis varies; however, an undoubtedly increasing trend has been reported, reflecting the aging population and greater recognition of this condition. Furthermore, treating sepsis patients creates a significant national financial burden.

Diabetes is an important comorbid condition in sepsis because of its high prevalence.^[@bibr5-2042018819875406]^ Diabetic patients are generally believed to be more prone to infections than the general population.^[@bibr6-2042018819875406]^ However, the influence of diabetes on the outcome of sepsis remains inconclusive. Higher mortality rates in patients with diabetes have been reported;^[@bibr7-2042018819875406][@bibr8-2042018819875406][@bibr9-2042018819875406][@bibr10-2042018819875406][@bibr11-2042018819875406]--[@bibr12-2042018819875406]^ however, other studies have found no effect of diabetes^[@bibr13-2042018819875406][@bibr14-2042018819875406][@bibr15-2042018819875406]--[@bibr16-2042018819875406]^ or even protective effects of diabetes on sepsis.^[@bibr17-2042018819875406][@bibr18-2042018819875406][@bibr19-2042018819875406]--[@bibr20-2042018819875406]^ Within this debate, the most frequently proposed study limitation was study design. Epidemiological studies using large cohorts can avoid the selection bias that is frequently observed in hospital-based studies, but detailed clinical information is usually not available. Most importantly, many studies have failed to consider the influence of diabetic complication severity.

Hemoglobin A1C (HbA1c) is commonly used to measure blood glucose control in diabetic patients and has also been proposed as an independent predictor of hospital mortality in sepsis patients.^[@bibr21-2042018819875406]^ However, its importance in diabetic sepsis patients requires further study because of limited data. Hyperglycemia has been shown to impair polymorphonuclear neutrophil function and cytokine production. However, high initial glucose levels were not reported to be associated with increased mortality in diabetic sepsis patients.^[@bibr22-2042018819875406]^ Furthermore, tight glucose control did not seem to be significantly associated with reduced hospital mortality in critical patients.^[@bibr23-2042018819875406],[@bibr24-2042018819875406]^ The influences of HbA1c and initial glucose levels on the outcome of sepsis deserve further investigation.

In the current study, using a representative nationwide database and a hospital-based database from multiple centers with laboratory data, we examined the association between type 2 diabetes and sepsis outcomes, specifically focusing on (a) whether type 2 diabetes itself increases the risk of mortality in hospitalized sepsis patients or whether risk of mortality depends on diabetic complication burdens, and (b) whether initial blood glucose level and HbA1c affect the hospital outcome.

Methods {#section6-2042018819875406}
=======

Data sources and study participants {#section7-2042018819875406}
-----------------------------------

In this study, we used two distinct databases: (a) the National Health Insurance Research Database (NHIRD), which included the Longitudinal Cohort of Diabetes Patients (LHDB) and the Longitudinal Health Insurance Database 2000 (LHID 2000); and (b) the hospital-based database from multiple centers.

Because the hospital-based database lacked longitudinal information for each type 2 diabetic individual, we used the LHDB and LHID 2000 to resolve this limitation. The LHDB and LHID 2000 recorded all the medical information for each individual, such as outpatient (at clinics or hospitals) and emergency department visits (at every hospital) and hospitalizations that were not limited to a single medical facility. Therefore, data from the NHIRD avoided recall bias and could be used in the longitudinal cohort study.

In contrast, the hospital-based database from multiple centers could provide laboratory data, such as HbA1c, initial blood glucose level, and culture results. However, the information was restricted to a single facility, and important information from other clinics or hospitals might be missed.

Nationwide database {#section8-2042018819875406}
-------------------

In the first part of this study, we conducted a nationwide cohort study using data from the NHIRD. The diagnosis codes of the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) are used in the NHIRD to identify specific diagnoses. Data for sepsis patients were retrieved using the ICD-9-CM code 038 plus a main infection diagnosis with antibiotics prescription. The accuracy of sepsis diagnosis in the NHIRD has been validated in previous studies.^[@bibr25-2042018819875406]^ The infection site classification was conducted following the criteria developed by Angus and colleagues.^[@bibr26-2042018819875406]^

The patients were classified as using certain drugs if they took the drugs for more than 1 month within a 1-year period prior to the index hospitalization (the first admission for sepsis). The index date was defined as the first day of index hospitalization. The drugs, procedures, special modalities, intensive care unit (ICU) admission, and length of hospital stay were recorded using the claims data of the NHIRD.

Initially, we used the LHDB of the NHIRD, which contains randomized selected data (a total of 1.68 million enrollees from 1999 to 2012) from patients with newly diagnosed diabetes to retrieve the study cohort of type 2 diabetic first-episode sepsis patients.^[@bibr27-2042018819875406]^ The patients in the study cohort had to have been diagnosed with type 2 diabetes at least 1 year prior to the index hospitalization to allow for the evaluation of diabetic complication burden by using the adjusted Diabetes Complications Severity Index score (aDCSI score).^[@bibr28-2042018819875406],[@bibr29-2042018819875406]^

The Diabetes Complications Severity Index (DCSI) was first developed by Young and coworkers.^[@bibr28-2042018819875406]^ The DCSI is a useful tool for adjusting for the baseline severity of diabetic complications and predicting hospital mortality. The aDCSI score was modified from the DCSI score and had been validated in the NHIRD.^[@bibr30-2042018819875406]^ The aDCSI score included seven categories of complications: cardiovascular disease, nephropathy, neuropathy, retinopathy, peripheral vascular disease, stroke, and metabolic emergency events.

The comparison cohort, which was composed of nondiabetic first-episode sepsis patients, was retrieved from the LHID 2000. The LHID 2000 used in this study contains medical information for 1 million beneficiaries, randomly sampled from the registry of all beneficiaries in 2000. The study cohort from the LHDB and the comparison cohort from the LHID 2000 were matched in a 1:1 ratio by propensity scoring. For each patient, we calculated the propensity score using multivariate logistic regression by entering age, sex, income, urbanization level, hospital level, baseline comorbidities, and infection sites from the LHDB and LHID 2000. This study was approved by the Institutional Review Board of China Medical University (CMUH104-REC2-115).

Hospital-based database {#section9-2042018819875406}
-----------------------

In the second part of this study, we retrieved the first-episode data of type 2 diabetic and nondiabetic sepsis patients from 2006 to 2012 in the electronic databases of three medical centers, Taipei and Taichung Veterans General Hospitals, and the Lin-Kou Medical Center of Chang Gung Memorial Hospital. The type 2 diabetic and nondiabetic sepsis patients were matched by age and sex. Laboratory data, including initial blood glucose level, HbA1c, and initial lactate level; hospital courses, including ICU admission and total and 28-day hospital mortality; received procedures (including mechanical ventilation and hemodialysis); and blood culture results were collected for further analysis. This study was approved by the Institutional Review Board of Taipei Veterans General Hospital (2018-02-003BC), Taichung Veterans General Hospital (CE18102A), and Lin-Kou Medical Center of Chang Gung Memorial Hospital (201701502B0C501).

The selection process of participants from the nationwide and hospital-based databases is shown in [Supplement Figure 1](http://journals.sagepub.com/doi/suppl/10.1177/2042018819875406). Most of the enrolled type 2 diabetic sepsis patients in the hospital database from multiple centers could be traced and linked to the nationwide database by a specific matching method.^[@bibr31-2042018819875406]^ However, matching was not allowed in Taiwan at the time of this study. Regarding the data in the hospital-based database, initial blood glucose levels were measured on the day of admission, either in the emergency department or on the ward, before patients received any acute glucose-lowering injection therapy (i.e. insulin). HbA1c levels were assessed during a 1-month period prior to the admission day.

### Statistical analyses {#section10-2042018819875406}

Differences in demographic characteristics, comorbidities, medications, and laboratory data were examined using the chi-square test, the Mann--Whitney test and a two-sample *t* test. Odds ratios (ORs) with 95% confidence intervals (95% CIs) were calculated using a logistic regression model. A Kaplan--Meier analysis with the log-rank test was performed to compare hospital outcomes among type 2 diabetic sepsis patients with different initial blood glucose levels and HbA1c values. Statistical analyses were performed using the SAS 9.4 statistical package (SAS Institute Inc., Cary, NC, USA). A *p* value of 0.05 was considered indicative of significance.

Results {#section11-2042018819875406}
=======

First part: nationwide database {#section12-2042018819875406}
-------------------------------

After propensity-score matching, data collected between 1999 and 2012 for 19,719 type 2 diabetic first-episode sepsis patients and an equal number of nondiabetic first-episode sepsis patients were retrieved as the study and comparison cohorts from the LHDB and LHID 2000. Demographic characteristics, comorbidities, medications, infection sites, and received procedures of the study and comparison cohorts are shown in [Table 1](#table1-2042018819875406){ref-type="table"}.

###### 

Nationwide database: demographic characteristics, comorbidities, and medications in type 2 diabetic and nondiabetic sepsis patients before and after propensity-score matching.

![](10.1177_2042018819875406-table1)

                                                                                      Before matching                   PS matching                                                                    
  ------------------------------------------------------------------- --------------- ----------------- --------------- ------------- --------------- --------------- -------- ------- ------- ------- -------
  **Sex**                                                                                                                                             \<0.0001                                         
  Female                                                              54,767          8913              41.31           45,854        46.38                           7990     40.52   7884    39.98   0.011
  Male                                                                65,672          12,663            58.69           53,009        53.62                           11729    59.48   11835   60.02   0.011
  **Age, years**                                                                                                                                      \<0.0001                                         
  20--29 years                                                        1529            953               4.42            576           0.58                            530      2.69    164     0.83    0.142
  30--39 years                                                        3892            1439              6.67            2453          2.48                            1077     5.46    631     3.2     0.111
  40--49 years                                                        9638            2106              9.76            7532          7.62                            1814     9.20    1755    8.9     0.01
  50--59 years                                                        17,755          2587              11.99           15,168        15.34                           2318     11.76   2910    14.76   0.089
  60--69 years                                                        22,552          2996              13.89           19,556        19.78                           2814     14.27   3694    18.73   0.12
  70--79 years                                                        33,327          5179              24              28,148        28.47                           5012     25.42   5404    27.41   0.045
  ⩾80 years                                                           31,746          6316              29.27           25,430        25.72                           6154     31.21   5161    26.17   0.112
  Mean (SD)^[\*](#table-fn2-2042018819875406){ref-type="table-fn"}^   68.90 (15.08)   66.89 (18.53)     69.33 (14.17)   \<0.0001      68.64 (17.39)   68.80 (14.88)   0.01                             
  **Insurance premium (NT dollars)**                                                                                                                  \<0.0001                                         
  \<20,000                                                            75,927          16,048            74.38           59,879        60.57                           14,576   73.92   14433   73.19   0.016
  20,000 ⩽ insurance premium \< 40,000                                36,824          4558              21.13           32,266        32.64                           4256     21.58   4365    22.14   0.013
  40,000 ⩽ insurance premium \<60,000                                 5930            890               4.12            5040          5.1                             820      4.16    839     4.25    0.005
  60,000 ⩽ insurance premium                                          1758            80                0.37            1678          1.7                             67       0.34    82      0.42    0.012
  **Urbanization level**                                                                                                                              \<0.0001                                         
   1 (highest)                                                        29,506          5407              25.1            24,099        24.38                           4902     24.86   4884    24.77   0.002
   2                                                                  33,242          5884              27.31           27,358        27.67                           5362     27.19   5306    26.91   0.006
   3                                                                  19,906          3487              16.18           16,419        16.61                           3180     16.13   3186    16.16   0.001
   4                                                                  19,589          3439              15.96           16150         16.34                           3199     16.22   3250    16.48   0.007
   5 (lowest)                                                         18,166          3329              15.45           14,837        15.01                           3076     15.6    3093    15.69   0.002
  **Hospital level**                                                                                                                                  \<0.0001                                         
  Medical center                                                      38,933          7570              35.09           31,363        31.72                           6836     34.67   6856    34.77   0.002
  Regional hospital                                                   54,017          9307              43.15           44,710        45.22                           8554     43.38   8554    43.38   0
  District hospital                                                   27,484          4694              21.76           22,790        23.05                           4329     21.95   4309    21.85   0.002
  **Baseline comorbidities**                                                                                                                                                                           
  HTN                                                                 86,491          12,782            59.24           73,709        74.56           \<0.0001        12,446   63.12   12360   62.68   0.009
  Hyperlipidemia                                                      51,971          5284              24.49           46,687        47.22           \<0.0001        5182     26.28   5148    26.11   0.004
  COPD                                                                52,796          9579              44.40           43,217        43.71           \<0.0001        9484     48.10   9524    48.30   0.004
  CLD                                                                 39,563          6605              30.61           32,958        33.34           \<0.0001        6518     33.05   6502    32.97   0.002
  CKD                                                                 46,873          5362              24.85           41,511        41.99           \<0.0001        5324     27.00   5334    27.05   0.001
  PAOD                                                                16,240          2036              9.44            14204         14.37           \<0.0001        2016     10.22   2014    10.21   0
  IHD                                                                 51,633          6852              31.76           44,781        45.30           \<0.0001        6783     34.40   6758    34.27   0.003
  Stroke                                                              52,615          8131              37.69           44,484        45.00           \<0.0001        8056     40.85   8071    40.93   0.002
  Cancer                                                              33,639          4452              20.63           29,187        29.52           \<0.0001        4422     22.43   4387    22.25   0.004
  **Drugs**                                                                                                                                                                                            
  NSAIDs                                                              59,580          10,021            46.45           49,559        50.13           \<0.0001        9588     48.62   9401    47.67   0.019
  Aspirin                                                             13,350          1980              9.18            11,370        11.50           \<0.0001        1938     9.83    2150    10.90   0.035
  Statins                                                             18,869          1014              4.70            17,855        18.06           \<0.0001        995      5.05    2178    11.05   0.222
  Biguanides                                                          42,469          --                --              42,469        42.96           --              --       --      7600    38.54   --
  DPP-4 inhibitors                                                    4759            --                --              4759          4.81            --              --       --      659     3.34    --
  Sulfonylureas                                                       47,483          --                --              47,483        48.03           --              --       --      8631    43.77   --
  TZDs                                                                6443            --                --              6443          6.52            --              --       --      961     4.87    --
  Other OADs                                                          18,113          --                --              18,113        18.32           --              --       --      2911    14.76   --
  Insulin                                                             34,201          --                --              34,201        34.59           --              --       --      6297    31.93   --
  Immunosuppressants                                                  447             74                0.34            373           0.38            0.4526          71       0.36    52      0.26    0.017
  Steroids                                                            29,167          4676              21.67           24,491        24.77           \<0.0001        4578     23.22   4681    23.74   0.012
  **Infection site**                                                                                                                                                                                   
  Respiratory                                                         44,511          8375              38.82           36,136        36.55           \<0.0001        7876     39.94   7420    37.63   0.047
  Genitourinary                                                       39,244          5979              27.71           33,265        33.65           \<0.0001        5419     27.48   6266    31.78   0.094
  Gastrointestinal                                                    9562            1817              8.42            7745          7.83            \<0.0001        1607     8.15    1672    8.48    0.012
  Soft tissue/musculoskeletal                                         6682            979               4.54            5703          5.77            \<0.0001        868      4.40    1239    6.28    0.084
  Central nervous                                                     785             135               0.63            650           0.66            \<0.0001        111      0.56    139     0.70    0.018
  Cardiovascular                                                      801             164               0.76            637           0.64            \<0.0001        143      0.73    135     0.68    0.005
  Device related                                                      1924            286               1.33            1638          1.66            \<0.0001        278      1.41    275     1.39    0.001
  Others                                                              10,006          1970              9.13            8036          8.13            \<0.0001        1745     8.85    1726    8.75    0.003
  **aDCSI score**                                                                                                                                                                                      
   0                                                                  24,134          --                --              24,134        24.41           --              --       --      5905    29.95   --
   1                                                                  11,625          --                --              11,625        11.76           --              --       --      2218    11.25   --
   2                                                                  25,030          --                --              25,030        25.32           --              --       --      5340    27.08   --
   3                                                                  10,782          --                --              10,782        10.91           --              --       --      1876    9.51    --
   4                                                                  14,575          --                --              14,575        14.74           --              --       --      2568    13.02   --
   ⩾5                                                                 12,171          --                --              12,171        12.86           --              --       --      1812    9.19    --
  **Procedures**                                                                                                                                                                                       
  Nasogastric tube feeding                                            71,665          12,314            57.07           59,351        60.03           \<0.0001                                         
  Central venous catheter insertion                                   49,283          8335              38.63           40,948        41.42           \<0.0001                                         
  Blood transfusion                                                   61,611          10,919            50.61           50,692        51.27           \<0.0001                                         
  Hemodialysis                                                        13,219          1786              8.28            11,433        11.56           \<0.0001                                         
  ICU admission                                                       59,583          10,060            46.63           49,523        50.09           0.0002                                           
  NIPPV                                                               8499            1456              6.75            7043          7.12            \<0.0001                                         
  Mechanical ventilation                                              47,205          8237              38.18           38,968        39.42           \<0.0001                                         

Results were obtained using the Chi-square test.

Results were obtained using the two-sample *t* test.

PS matching include variables of age, sex, insurance premium, urbanization level, hospital level, baseline comorbidities, and infection site.

aDSCI, adapted Diabetes Complications Severity Index; CKD, chronic kidney disease; CLD, chronic liver disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; DPP-4 inhibitors, dipeptidyl peptidase-4 inhibitor; HTN, hypertension; ICU, intensive care unit; IHD, ischemic heart disease; NIPPV, non-invasive positive pressure ventilation; NT dollars, national Taiwan dollars; OADs, oral antidiabetic drugs; PAOD, peripheral arterial occlusion disease; PS, propensity score; TZD, thiazolidinedione.

Before matching, the type 2 diabetic sepsis patients had a higher prevalence of sepsis in the genitourinary tract (33.65% *versus* 27.71%) and soft tissue/musculoskeletal system (5.77% *versus* 4.54%, both *p* \< 0.0001). Additionally, the diabetic sepsis patients more frequently received respiratory support (mechanical ventilation: 39.42% *versus* 38.18%; noninvasive positive pressure ventilation: 7.12% *versus* 6.75%, both *p* \< 0.0001) and dialysis (11.56% *versus* 8.28%, *p* \< 0.0001) compared with the nondiabetic sepsis patients.

After propensity-score matching in a multivariate analysis, type 2 diabetic sepsis patients had an increased OR of 1.14 (95% CI 1.10--1.19, *p* \< 0.0001) for mortality after adjusting for age, sex, insurance premium (as a proxy for household income), urbanization level, and hospital level ([Table 2](#table2-2042018819875406){ref-type="table"}).

###### 

Nationwide database: odds ratio of mortality related to type 2 diabetes and its complication severity in different adjusted models.

![](10.1177_2042018819875406-table2)

  Characteristics                          Die (*n* = 16205)   Crude   Adjusted model 1   Adjusted model 2                                                          
  ---------------------------------------- ------------------- ------- ------------------ ------------------ ------ -------------- ---------- ------ -------------- ----------
  **DM**                                                                                                                                                            
   No                                      7811                1.00    Reference                             1.00   Reference                 1.00   Reference      
   Yes                                     8394                1.13    (1.09--1.18)       \<0.0001           1.14   (1.1--1.19)    \<0.0001   --     --             --
  **aDCSI score**                                                                                                                                                   
   0                                       2034                0.80    (0.75--0.85)       \<0.0001           --     --             --         0.91   (0.85--0.97)   0.0033
   1                                       781                 0.83    (0.76--0.91)       \<0.0001           --     --             --         0.87   (0.8--0.96)    0.0053
   2                                       2299                1.15    (1.08--1.23)       \<0.0001           --     --             --         1.14   (1.07--1.22)   \<0.0001
   3                                       875                 1.33    (1.21--1.47)       \<0.0001           --     --             --         1.25   (1.13--1.38)   \<0.0001
   4                                       1376                1.76    (1.62--1.91)       \<0.0001           --     --             --         1.56   (1.43--1.7)    \<0.0001
   ⩾5                                      1029                2.00    (1.82--2.21)       \<0.0001           --     --             --         1.77   (1.61--1.96)   \<0.0001
  **Sex**                                                                                                                                                           
  Female                                   5685                1.00    Reference                             1.00   Reference                 1.00   Reference      
  Male                                     10,520              1.45    (1.39--1.51)       \<0.0001           1.56   (1.5--1.63)    \<0.0001   1.55   (1.49--1.62)   \<0.0001
  **Age, years**                                                                                                                                                    
  20--29 years                             121                 1.00    Reference                             1.00   Reference                 1.00   Reference      
  30--39 years                             385                 1.38    (1.1--1.73)        0.0055             1.37   (1.09--1.72)   0.0071     1.38   (1.1--1.74)    0.0053
  40--49 years                             1090                2.08    (1.69--2.57)       \<0.0001           2.07   (1.68--2.56)   \<0.0001   2.11   (1.71--2.61)   \<0.0001
  50--59 years                             1616                2.12    (1.73--2.6)        \<0.0001           2.19   (1.78--2.69)   \<0.0001   2.21   (1.8--2.72)    \<0.0001
  60--69 years                             2372                2.72    (2.22--3.33)       \<0.0001           2.72   (2.22--3.33)   \<0.0001   2.71   (2.21--3.32)   \<0.0001
  70--79 years                             4635                3.80    (3.11--4.64)       \<0.0001           3.69   (3.02--4.51)   \<0.0001   3.57   (2.92--4.37)   \<0.0001
  ⩾80 years                                5986                5.32    (4.36--6.49)       \<0.0001           5.33   (4.36--6.52)   \<0.0001   5.10   (4.17--6.24)   \<0.0001
  **Insurance premium (NT dollars)**                                                                                                                                
  \<20000                                  12,766              1.00    Reference                             1.00   Reference                 1.00   Reference      
  20,000 ⩽ insurance premium \< 40,000     2937                0.66    (0.63--0.69)       \<0.0001           0.71   (0.68--0.75)   \<0.0001   0.72   (0.68--0.76)   \<0.0001
  40,000 ⩽ insurance premium \< 60,000     458                 0.49    (0.43--0.54)       \<0.0001           0.60   (0.54--0.68)   \<0.0001   0.62   (0.55--0.69)   \<0.0001
  60,000 ⩽ insurance premium               44                  0.53    (0.37--0.76)       0.0005             0.67   (0.47--0.96)   0.0271     0.70   (0.49--1)      0.0521
  **Urbanization level**                                                                                                                                            
   1 (highest)                             4004                1.00    Reference                             1.00   Reference                 1.00   Reference      
   2                                       4274                0.97    (0.91--1.02)       0.2171             1.00   (0.94--1.06)   0.9948     1.01   (0.95--1.07)   0.86
   3                                       2655                1.03    (0.97--1.1)        0.3179             1.05   (0.98--1.12)   0.134      1.06   (0.99--1.13)   0.1103
   4                                       2692                1.03    (0.97--1.1)        0.2939             1.03   (0.96--1.1)    0.3671     1.04   (0.97--1.11)   0.2698
   5 (lowest)                              2580                1.04    (0.97--1.11)       0.2565             1.06   (0.99--1.14)   0.0723     1.07   (1--1.15)      0.0409
  **Hospital level**                                                                                                                                                
  Medical center                           5705                1.00    Reference                             1.00   Reference                 1.00   Reference      
  Regional hospital                        6894                0.94    (0.9--0.99)        0.0152             0.88   (0.84--0.92)   \<0.0001   0.87   (0.83--0.92)   \<0.0001
  District hospital                        3606                1.00    (0.95--1.06)       0.9066             0.83   (0.78--0.88)   \<0.0001   0.81   (0.77--0.86)   \<0.0001
  **Baseline comorbidities**                                                                                                                                        
  HTN                                      10,716              1.27    (1.21--1.32)       \<0.0001           0.95   (0.89--1.01)   0.1142     --     --             --
  Hyperlipidemia                           3820                0.79    (0.76--0.83)       \<0.0001           0.90   (0.84--0.96)   0.0014     --     --             --
  COPD                                     8647                1.42    (1.37--1.48)       \<0.0001           0.91   (0.86--0.97)   0.0018     --     --             --
  CLD                                      5444                1.05    (1--1.09)          0.0403             1.09   (1.03--1.16)   0.0045     --     --             --
  CKD                                      5031                1.41    (1.35--1.47)       \<0.0001           0.99   (0.93--1.06)   0.7966     --     --             --
  PAOD                                     1910                1.33    (1.25--1.42)       \<0.0001           1.08   (0.99--1.18)   0.085      --     --             --
  IHD                                      6116                1.29    (1.24--1.35)       \<0.0001           0.95   (0.89--1.01)   0.1177     --     --             --
  Cancer                                   4836                2.06    (1.97--2.16)       \<0.0001           3.02   (2.83--3.22)   \<0.0001   --     --             --
  Stroke                                   7409                1.40    (1.35--1.46)       \<0.0001           1.21   (1.16--1.27)   \<0.0001   --     --             --
  **Procedures**                                                                                                                                                    
  Nasogastric tube feeding                 13,777              7.84    (7.46--8.25)       \<0.0001           --     --             --         --     --             --
  Central venous catheter insertion        9973                4.74    (4.54--4.95)       \<0.0001           --     --             --         --     --             --
  Blood transfusion                        11,716              4.01    (3.84--4.19)       \<0.0001                                                                  
  Hemodialysis                             2236                2.83    (2.63--3.04)       \<0.0001           --     --             --         --     --             --
  ICU admission                            10,893              3.87    (3.71--4.03)       \<0.0001                                                                  
  NIPPV                                    1591                2.14    (1.98--2.32)       \<0.0001                                                                  
  Mechanical ventilation                   10,564              6.62    (6.33--6.92)       \<0.0001           --     --             --         --     --             --
  Cardiopulmonary cerebral resuscitation   3893                10.36   (9.52--11.27)      \<0.0001           --     --             --         --     --             --

Model 1: adjusted for DM, age, sex, insurance premium, urbanization level, hospital level, and baseline comorbidities.

Model 2: adjusted for aDSCI score, age, sex, insurance premium, urbanization level, and hospital level.

In model 2, baseline comorbidities were not put into the model for adjustment because of the collinearity.

aDSCI, adapted Diabetes Complications Severity Index; CI, confidence interval; CKD, chronic kidney disease; CLD, chronic liver disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; HTN, hypertension; ICU, intensive care unit; IHD, ischemic heart disease; NIPPV, non-invasive positive pressure ventilation, NT dollars, national Taiwan dollars; OR, odds ratio; PAOD, peripheral arterial occlusion disease.

According to diabetic complication burdens in the regression analysis of the main model, the patients with aDCSI scores of 0, 1, 2, 3, 4, and ⩾5 had ORs of 0.91 (95% CI 0.85--0.97), 0.87 (95% CI 0.80--0.96), 1.14 (95% CI 1.07--1.22), 1.25 (95% CI 1.13--1.38), 1.56 (95% CI 1.43--1.70), and 1.77 (95% CI 1.61--1.96) for hospital mortality of sepsis, respectively (all *p* \< 0.001 and *p* for trend \< 0.001). In the subgroup analysis, the type 2 diabetic sepsis patients with higher aDCSI scores had increased ORs for mortality compared with those with lower scores in every age subgroup (per 10 years), especially in the range of 30--39 years ([Supplement Figure 2](http://journals.sagepub.com/doi/suppl/10.1177/2042018819875406)).

We also stratified the sepsis patients according to infection site, and we found that the type 2 diabetic sepsis patients had increased adjusted ORs in every origin except the gastrointestinal system (adjusted OR of 2.29 (95% CI 1.36--3.86) for the central nervous system, adjusted OR of 1.26 (95% CI 1.18--1.35) for the respiratory system, adjusted OR of 1.88 (95% CI 1.14--3.10) for the cardiovascular system, adjusted OR of 1.58 (95% CI 1.46--1.72) for the genitourinary system, adjusted OR of 1.32 (95% CI 1.08--1.61) for soft tissue, and adjusted OR of 0.99 (95% CI 0.86--1.14) for the gastrointestinal system; [Supplement Table 1](http://journals.sagepub.com/doi/suppl/10.1177/2042018819875406)).

Second part: hospital-based database {#section13-2042018819875406}
------------------------------------

From the hospital-based database, we initially included data for 4984 sepsis patients collected between 2006 and 2012. After matching for age and sex, 1054 type 2 diabetic sepsis patients and 2108 nondiabetic sepsis patients were included for further analysis.

The type 2 diabetic sepsis patients had a higher initial creatinine level (2.4 ± 2.1 *versus* 1.9 ± 1.8, *p* \< 0.001) and prevalence of receiving hemodialysis during hospitalization (23.2% *versus* 16.9%, *p* \< 0.001; [Table 3](#table3-2042018819875406){ref-type="table"}). Furthermore, the type 2 diabetic sepsis patients had a higher ICU admission rate (57.5% *versus* 55.3%, *p* = 0.249) and acute physiologic and chronic health II (APACH II) score (25.3 ± 7.1 *versus* 24.9 ± 7.0, *p* = 0.292) than the nondiabetic sepsis patients, although the *p* value did not reach significance. Accordingly, the type 2 diabetic sepsis patients had a higher hospital mortality rate (45.2% *versus* 42.3%, *p* = 0.138) and 28-day mortality rate (35.5% *versus* 32.8%, *p* = 0.147) than the nondiabetic sepsis patients. The type 2 diabetic sepsis patients had a higher prevalence of Gram-positive coccus bacteremia (16.8% *versus* 14.4%, *p* = 0.089) but a lower prevalence of Gram-negative bacillus bacteremia (19.1% *versus* 20.7%, *p* = 0.294) than the nondiabetic sepsis patients.

###### 

Demographic characteristics, comorbidities, laboratory data, hospital course, and outcomes of matched type 2 diabetic and nondiabetic sepsis patients.

![](10.1177_2042018819875406-table3)

  --------------------------------------------------------------------------------------------------------------------------------------------------
  Variables                                                                            Total (*n* = 3162)   DM              *p* value      
  ------------------------------------------------------------------------------------ -------------------- --------------- -------------- ---------
  Age^[¶](#table-fn10-2042018819875406){ref-type="table-fn"}^                          70.4 ± 13.1          70.3 ± 12.9     70.4 ± 13.1    0.779

  Male                                                                                 1956 (61.9)          652 (61.9)      1304 (61.9)    1.000

  Hospital mortality                                                                   1368 (43.3)          476 (45.2)      892 (42.3)     0.138

   28-day mortality                                                                    1066 (33.7)          374 (35.5)      692 (32.8)     0.147

  Hemodialysis                                                                         602 (19.0)           245 (23.2)      357 (16.9)     \<0.001

  Mechanical ventilation                                                               1897 (60.0)          658 (62.4)      1239 (58.8)    0.053

  ICU admission                                                                        1771 (56.0)          606 (57.5)      1165 (55.3)    0.249

   APACH II score\                                                                     25.0 ± 7.0           25.3 ± 7.1      24.9 ±7.0      0.292
   (*n* = 557 *versus* 1063)^[¶](#table-fn10-2042018819875406){ref-type="table-fn"}^                                                       

   Length of ICU stay^[¶](#table-fn10-2042018819875406){ref-type="table-fn"}^          15.6 ± 14.3          14.6 ± 13.8     16.0 ± 14.6    0.020

   Length of hospital stay^[¶](#table-fn10-2042018819875406){ref-type="table-fn"}^     23.5 ±25.5           23.0 ± 27.5     23.7 ± 24.4    0.214

  **Comorbidities**                                                                                                                        

  HTN                                                                                  931 (29.4)           463 (43.9)      468 (22.2)     \<0.001

  Hyperlipidemia                                                                       54 (1.7)             36 (3.4)        18 (0.9)       \<0.001

  COPD                                                                                 287 (9.1)            72 (6.8)        215 (10.2)     0.002

  CLD                                                                                  244 (7.7)            81 (7.7)        163 (7.7)      1.000

  CKD                                                                                  1019 (32.2)          410 (38.9)      609 (28.9)     \<0.001

  PAOD                                                                                 80 (2.5)             43 (4.1)        37 (1.8)       \<0.001

  IHD                                                                                  124 (3.9)            55 (5.2)        69 (3.3)       0.010

  Cancer                                                                               958 (30.3)           226 (21.4)      732 (34.7)     \<0.001

  Stroke                                                                               273 (8.6)            120 (11.4)      153 (7.3)      \<0.001

  CCI score^[¶](#table-fn10-2042018819875406){ref-type="table-fn"}^                    3.4 ± 2.7            3.7 ± 2.4       3.2 ± 2.8      \<0.001

  **Bacterial cultures**                                                                                                                   

  GPC                                                                                  481 (15.2)           177 (16.8)      304 (14.4)     0.089

  GNB                                                                                  638 (20.2)           201 (19.1)      437 (20.7)     0.294

  **Laboratory data**                                                                                                                      

  Glucose                                                                              191.4 ± 141.8        270.4 ± 189.4   149.1 ± 80.8   \<0.001

  WBC (×10^3^)                                                                         13.2 ±13.5           14.2 ± 12.1     12.7 ±14.1     \<0.001

  Hb                                                                                   12.0 ± 2.7           12.2 ± 2.6      12.0 ± 2.7     0.057

  PLT (×10^6^)                                                                         1.9 ± 1.3            2.1 ± 1.6       1.9 ± 1.2      \<0.001

  Cr                                                                                   2.1 ± 1.9            2.4 ± 2.1       1.9 ±1.8       \<0.001

  Bilirubin                                                                            0.9 ± 2.0            0.8 ± 1.9       0.9 ± 2.0      \<0.001

  Lactate                                                                              31.7 ± 31.3          32.9 ± 34.0     31.0 ± 29.7    0.259
  --------------------------------------------------------------------------------------------------------------------------------------------------

Results were obtained using the Chi-square test.

Results were obtained using the Mann--Whitney test.

Continuous data are expressed as mean ± SD. Categorical data are expressed as numbers (percentage).

APACH, acute physiologic and chronic health; CCI, Charlson comorbidity index; CKD, chronic kidney disease; CLD, chronic liver disease; COPD, chronic obstructive pulmonary disease; Cr, creatinine; DM, diabetes mellitus; GNB, Gram-negative bacillus (GNB); GPC, Gram-positive coccus; Hb, hemoglobin; HTN, hypertension; ICU, intensive care unit; IHD, ischemic heart disease; PAOD, peripheral arterial occlusion disease; PLT, platelets; SD, standard deviation; WBC, white blood count.

In the univariate and multivariate logistic regression analyses, type 2 diabetes was associated with an increased risk of hospital mortality during the sepsis course (adjusted OR = 1.31, 95% CI 1.11--1.54, *p* = 0.002). This result was similar to that obtained for the nationwide database. The Kaplan--Meier analysis with log-rank test also showed a difference in hospital mortality between the type 2 diabetic and nondiabetic sepsis patients \[*p* = 0.122; [Figure 1(a)](#fig1-2042018819875406){ref-type="fig"}\].

![Diabetic sepsis patients' initial glucose.\
(a) The Kaplan--Meier analysis with log-rank test showed the difference in the hospital course of mortality between the type 2 diabetic and nondiabetic sepsis patients. (b) Scatter plot of initial blood glucose levels in the surviving and deceased type 2 diabetic sepsis patients, which did not differ significantly: 273.9 ± 180.3 mg/dl *versus* 266.1 ± 200.2 mg/dl (*p* = 0.095).](10.1177_2042018819875406-fig1){#fig1-2042018819875406}

The 1054 type 2 diabetic sepsis patients were divided into two groups, surviving and deceased patients, for further comparison. Initial blood glucose levels between the surviving and deceased diabetic sepsis patient groups did not differ significantly: 273.9 ± 180.3 *versus* 266.1 ± 200.2 \[mg/dl; *p* = 0.095; [Figure 1(b)](#fig1-2042018819875406){ref-type="fig"}\]. Furthermore, the surviving diabetic sepsis patients did not have lower HbA1c (%) levels than the deceased diabetic sepsis patients: 8.4 ± 2.6 *versus* 8.0 ± 2.5 (*p* = 0.078; [Supplement Table 2](http://journals.sagepub.com/doi/suppl/10.1177/2042018819875406)). The univariate analysis, another logistic regression analysis that included age, sex, Charlson comorbidity index score, and important laboratory data, showed an OR of 1.00 (95% CI 1.00--1.00, *p* = 0.532) for initial glucose levels and 0.94 (95% CI 0.86--1.02, *p* = 0.143) for HbA1c. The Kaplan--Meier analysis with log-rank test also showed that hospital mortality did not differ among type 2 diabetic sepsis patients with different initial blood glucose levels (⩽200, 201--400, and \>400 mg/dl) and HbA1c values (⩽7 and \>7%) \[[Figure 2(a)](#fig2-2042018819875406){ref-type="fig"} and ([b](#fig2-2042018819875406){ref-type="fig"})\].

![Survival rate *versus* glucose and HbA1c.\
(a) The Kaplan--Meier analysis with log-rank test for the hospital course of mortality among type 2 diabetic sepsis patients with different initial blood glucose levels at admission (⩽200, 201--400, and \>400). (b) The Kaplan--Meier analysis with log-rank test for the hospital course of mortality between type 2 diabetic sepsis patients with HbA1c levels \> 7 and ⩽7.](10.1177_2042018819875406-fig2){#fig2-2042018819875406}

Sensitivity analysis {#section14-2042018819875406}
--------------------

We analyzed multiple models adjusted for drugs, procedures, and infection sites to examine the stability of the main model, that is, the multivariate analysis based on the aDCSI score. The models showed that the hospital mortality rate of sepsis increased as the aDCSI score increased ([Supplement Table 3](http://journals.sagepub.com/doi/suppl/10.1177/2042018819875406)).

In the sensitivity analysis, we used a stricter inclusion criterion for HbA1c collection: the HbA1c needed to be collected within 3 days of admission. A total of 366 (sample size reduced from 953 to 366) type 2 diabetic sepsis patients were included. The difference in hospital mortality rate remained unchanged (a hospital mortality rate of 39.5% for HbA1c ⩽ 7 and 35.2% for HbA1c \> 7). In addition, we conducted another sensitivity analysis that excluded the outlier subjects with initial blood sugar levels \> 600 or \<50 mg/dl. The study results remained unchanged (for initial blood glucose levels ⩽200, 201--400, and \>400 mg/dl, the hospital mortality rates were 48.2%, 41.2%, and 48.1%, respectively, *p* = 0.136).

Discussion {#section15-2042018819875406}
==========

In this study, we demonstrated that the outcome of type 2 diabetic sepsis patients was mainly determined by the cumulative diabetic complication burden (represented by the aDCSI score) rather than diabetes itself. The above argument was reinforced by the reverse ORs found in the type 2 diabetic sepsis patients with an aDCSI score ⩽ 1. In other words, if type 2 diabetic patients have few complications, they may not have an inferior hospital outcome of sepsis compared with nondiabetic patients. Furthermore, somewhat surprisingly, neither recent glucose control (HbA1c) nor the initial blood glucose level was associated with hospital mortality during the sepsis course. In conclusion, clinicians should not infer the outcome of a type 2 diabetic sepsis patient merely on the basis of recent glucose control or initial glucose level; rather, they should consider the cumulative diabetic complication burden. The stereotype of the impact of type 2 diabetes in sepsis should be modified.

This study contributes at least two important novelties in clinical practice. First, we described the trajectory of type 2 diabetic sepsis patients from the past (cumulative diabetic complication burdens) to the recent past (blood glucose control within the prior 3 months, HbA1c) and the present (initial blood glucose at admission). The connections were bridged by using the nationwide diabetic patient database and the multicenter hospital databases concurrently. Second, we evaluated the severity of type 2 diabetic patients by using the aDCSI score, which is specific for the evaluation of diabetic complication burdens, and we explored its use in sepsis outcome predictions.

Donnelly and colleagues demonstrated that diabetes was associated with an increased risk of hospitalization due to infectious diseases. However, diabetes itself and insulin use were not associated with increased 28-day hospital mortality.^[@bibr32-2042018819875406]^ Nonetheless, Dianna and coworkers demonstrated that patients with diabetes had an excess risk of dying from a range of infectious diseases.^[@bibr33-2042018819875406]^ Both studies used a large cohort, but their conclusions were conflicting. We infer that the difference was due to the lack of a classification of diabetes severity. In our study, we introduced the use of the aDCSI score, and the results showed that the sepsis outcomes of diabetic patients were mainly determined by the complication burden of diabetes. Our argument was also supported by the dose--response effect in the trend test for the ORs of patients with different aDCSI scores. Therefore, judging the sepsis outcome only by the existence of diabetes is not sufficient.

HbA1c is a widely used marker that reflects the average glucose level within the previous 120 days. Furthermore, HbA1c was reported a major outcome predictor in diabetic sepsis patients.^[@bibr21-2042018819875406]^ However, our study results did not support this argument. Many studies support the influence of long-term glycemic control on diabetic complication development.^[@bibr34-2042018819875406],[@bibr35-2042018819875406]^ Poor long-term glycemic control makes diabetic patients prone to infectious diseases because of their impaired immune functions.^[@bibr32-2042018819875406]^ In this study, HbA1c levels were assessed during a 1-month period prior to the admission day. In Taiwan, because of the convenience and high quality of medical care, the diabetes specialists were easily accessed without the need of long waiting. Patients could receive antidiabetic drug adjustment according to the HbA1c level in the outpatient department on time. Furthermore, the diabetic sepsis patients presenting with higher HbA1c levels may receive more aggressive blood sugar control with insulin in the initial stage of sepsis. Although, the hospital outcome of diabetic sepsis patients with higher HbA1c was not be as poor as initially thought, more evidence was needed to document this result.

Hyperglycemia frequently occurs in sepsis patients as a stress response that stimulates gluconeogenesis, which uses recycled pyruvate and lactate.^[@bibr36-2042018819875406][@bibr37-2042018819875406]--[@bibr38-2042018819875406]^ Hyperglycemia may have protective effects in patients because high blood glucose levels increase the diffusion gradient in tissues with abnormal microvasculature caused by sepsis. Our study may indirectly support the above argument. A study by van Vught and colleagues demonstrated that admission hyperglycemia was associated with adverse outcomes in sepsis, irrespective of the presence of diabetes.^[@bibr39-2042018819875406]^ However, our study demonstrated that a high blood glucose level at admission was not associated with hospital outcome. We inferred that the initial blood glucose level was an important risk factor for mortality in nondiabetic sepsis patients but not in type 2 diabetic sepsis patients.

Our study has the following strengths. In the study of the nationwide database, we used claims data for procedures such as mechanical ventilation, hemodialysis, and blood transfusion. The accuracy of this approach is far superior to using only ICD-9 or 10 codes for acute organ dysfunction. Furthermore, detailed information, such as blood culture results and APACH II scores, in the hospital-based database provided a richer understanding of the complex interplay between type 2 diabetes and sepsis, rather than simple taxonomy.

This study is not without limitations. We were able to link the individual patient's medical information between the hospital-based database and the nationwide diabetic patient database to create a convincing longitudinal cohort study. However, due to the increasing conflict surrounding healthcare database use in Taiwan, we abandoned this idea to avoid further severe debates. Second, some may challenge our use of a previous sepsis definition, originating from the systemic inflammatory response syndrome (SIRS) criteria, rather than the sepsis-3 definition. However, we believe that the central idea of this study would not change. We retrieved the study cohort by using ICD-9 codes not only for sepsis (038) but also for main infection origins, such as pneumonia or biliary tract infection. Therefore, we are confident that all the retrieved sepsis patients in our study were truly infected and did not have other conditions, such as pancreatitis, burn injury, or trauma, which would similarly induce SIRS reactions. Furthermore, as noted by Cortes-Puch I and coworkers, 'Moreover, these previous definitions and the SIRS criteria have been widely adopted for use at the bedside and for hospital and statewide quality improvement initiatives worldwide. Numerous controlled trials have relied on them, and this scientific database should not be discarded until unequivocal evidence indicates that superior diagnostic criteria exist.'^[@bibr40-2042018819875406]^ We believe that our study could still provide valuable information to clinicians. Finally, the first sodium--glucose cotransporter-2 (SGLT2) inhibitor (Empagliflozin) was available in Taiwan since 2014. However, our nationwide database only included the data from 1999 to 2012. Therefore, we could not discuss the potential risk of serious urinary tract infections and genital infections in type 2 diabetic patients using SGLT2 inhibitors.

Conclusion {#section16-2042018819875406}
==========

In type 2 diabetic sepsis patients, hospital mortality was mainly determined by the diabetes-related complication burden rather than the diabetes itself. Furthermore, initial blood glucose and HbA1c levels may not be as important as previously thought. Early intervention in type 2 diabetic patients could clearly improve the sepsis outcome, especially in the early stage of diabetes with few diabetic complications.
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